Drug Design, Development and Therapy, 1177-8881

Journal

More filtering options
  1. 2021
  2. A review of romiplostim mechanism of action and clinical applicability

    James B. Bussel, Gerald Soff, Adriana Balduzzi, Nichola Cooper, Tatiana Lawrence & John W. Semple, 2021, In: Drug Design, Development and Therapy. 15, p. 2243-2268 26 p.

    Research output: Contribution to journalReview article

  3. 2019
  4. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies

    Tao Wang, Jie Yu, Min Liu, Yanliang Chen, Caiyun Zhu, Lin Lu, Mingzhu Wang, Lingfeng Min, Xinxin Liu, Xizhi Zhang, Johannes A. Gubat & Yong Chen, 2019, In: Drug Design, Development and Therapy. 13, p. 539-553 15 p.

    Research output: Contribution to journalArticle

  5. 2016
  6. Two phase ii randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma

    Piotr Kuna, Leif Bjermer & Göran Tornling, 2016 Aug 31, In: Drug Design, Development and Therapy. 10, p. 2759-2770 12 p.

    Research output: Contribution to journalArticle

  7. 2015
  8. Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA).

    Leif Bjermer, Piotr Kuna, Carin Jorup, Thomas Bengtsson & Johan Rosenborg, 2015, In: Drug Design, Development and Therapy. 9, p. 753-762

    Research output: Contribution to journalArticle

  9. 2013
  10. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer

    Julius Semenas, Nishtman Dizeyi & Jenny L Persson, 2013, In: Drug Design, Development and Therapy. 7, p. 875-881

    Research output: Contribution to journalReview article